Boston Scientific Balance Sheet
BSX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.
Boston Scientific had $43.7B in total assets and $24.2B in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.0B | $414.0M | $865.0M | $928.0M | $1.7B | $217.0M | $217.0M | $146.0M | $188.0M | $196.0M | $319.0M | $587.0M | $217.0M | $207.0M | $267.0M |
| Inventory | $2.9B | $2.8B | $2.5B | $1.9B | $1.6B | $1.4B | $1.6B | $1.2B | $1.1B | $955.0M | $1.0B | $946.0M | $897.0M | $884.0M | $931.0M |
| Current Assets | $8.8B | $6.9B | $6.5B | $5.8B | $6.3B | $6.7B | $4.7B | $4.0B | $3.8B | $3.2B | $3.5B | $3.6B | $3.0B | $3.0B | $3.1B |
| PP&E (Net) | $4.0B | $3.3B | $2.9B | $2.4B | $2.3B | $2.1B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B | $1.5B | $1.5B | $1.6B | $1.7B |
| Goodwill | $18.3B | $17.1B | $14.4B | $12.9B | $10.0B | $10.2B | $10.2B | $7.9B | $7.0B | $6.7B | $6.5B | $5.9B | $5.7B | $6.0B | $9.8B |
| Total Assets | $43.7B | $39.4B | $35.1B | $32.5B | $32.2B | $30.8B | $30.6B | $21.0B | $19.0B | $18.1B | $18.1B | $17.0B | $16.6B | $17.2B | $21.3B |
| Current Liabilities | $5.4B | $6.4B | $4.9B | $3.8B | $4.3B | $3.7B | $4.9B | $5.3B | $5.7B | $3.6B | $2.4B | $2.8B | $1.8B | $1.8B | $1.8B |
| Total Debt | - | - | - | - | - | - | - | - | $3.8B | $5.4B | $5.7B | $4.2B | $4.2B | $4.2B | $4.2B |
| Shareholders' Equity | $24.2B | $21.8B | $19.3B | $17.6B | $15.3B | $13.9B | $13.9B | $8.7B | $7.0B | $6.7B | $6.3B | $6.5B | $6.5B | $6.9B | $11.4B |